Definium Therapeutics (DFTX) Stock Forecast & Price Target

Compare

2,168 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DFTX Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Definium

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DFTX Stock 12 Month Forecast

Average Price Target

$32.58

▲(93.49% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Definium Therapeutics in the last 3 months. The average price target is $32.58 with a high forecast of $61.00 and a low forecast of $18.00. The average price target represents a 93.49% change from the last price of $16.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","33":"$33","62":"$62","18.5":"$18.5","47.5":"$47.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.583333333333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,18.5,33,47.5,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.39,17.052307692307693,20.714615384615385,24.376923076923077,28.03923076923077,31.701538461538462,35.363846153846154,39.026153846153846,42.68846153846154,46.35076923076923,50.01307692307692,53.675384615384615,57.33769230769231,{"y":61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.39,14.866410256410257,16.342820512820513,17.81923076923077,19.295641025641025,20.772051282051283,22.24846153846154,23.724871794871795,25.201282051282053,26.67769230769231,28.154102564102566,29.630512820512823,31.10692307692308,{"y":32.583333333333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.39,13.744615384615384,14.09923076923077,14.453846153846154,14.80846153846154,15.163076923076924,15.517692307692307,15.872307692307693,16.22692307692308,16.58153846153846,16.936153846153847,17.29076923076923,17.645384615384614,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$61.00

Average Price Target$32.58

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Tsai

Jefferies

$30

Buy

78.15%

Upside

Initiated

01/30/26

Definium Therapeutics initiated with a Buy at JefferiesDefinium Therapeutics initiated with a Buy at Jefferies

Unknown Analyst

Robert W. Baird

Not Ranked

Robert W. Baird

$16→$37

Buy

119.71%

Upside

Reiterated

01/29/26

Definium Therapeutics price target raised to $37 from $16 at BairdDefinium Therapeutics price target raised to $37 from $16 at Baird

Patrick Trucchio

H.C. Wainwright

$55

Buy

226.60%

Upside

Reiterated

01/28/26

Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Definium Therapeutics (DFTX)

Brian Abrahams

RBC Capital

$20→$36

Buy

113.78%

Upside

Reiterated

01/23/26

RBC Capital Sticks to Their Buy Rating for Definium Therapeutics (DFTX)

Justin Walsh

JonesTrading

$61

Buy

262.23%

Upside

Reiterated

01/20/26

Definium Therapeutics: Advancing Late-Stage Psychedelic Pipeline and Diversifying Assets Underpin Buy Rating and $61 Target

Ami Fadia

Needham

$28

Buy

66.27%

Upside

Reiterated

01/12/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Francois Brisebois

LifeSci Capital

$32

Buy

90.02%

Upside

Reiterated

01/12/26

Definium Therapeutics: De-Risked Late-Stage Neuropsychiatric Pipeline Positions 2026 as Catalyst-Rich Year Supporting Buy Rating and $32 Target

Rudy Li

Chardan Capital

$20

Buy

18.76%

Upside

Initiated

12/31/25

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT) and Mind Medicine (NASDAQ: MNMD)

Gavin Clark-Gartner

Evercore ISI

$23→$24

Buy

42.52%

Upside

Reiterated

12/18/25

Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Mind Medicine (NASDAQ: MNMD)

Michael Okunewitch

Maxim Group

$18

Buy

6.89%

Upside

Reiterated

11/10/25

Mind Medicine's Strong Financial Position and Clinical Progress Drive Buy Rating

Jay Olson

Oppenheimer

$25

Buy

48.46%

Upside

Reiterated

11/07/25

Oppenheimer Sticks to Its Buy Rating for Mind Medicine (MNMD)

Sumant Kulkarni

Canaccord Genuity

$16→$25

Buy

48.46%

Upside

Reiterated

11/07/25

Mind Medicine price target raised to $25 from $16 at CanaccordMind Medicine price target raised to $25 from $16 at Canaccord

Jason Wittes

Roth MKM

$36

Buy

113.78%

Upside

Reiterated

08/04/25

Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM)

Marc Goodman

Leerink Partners

$20

Buy

18.76%

Upside

Reiterated

08/01/25

Mind Medicine's Promising Pipeline and Financial Stability Drive Buy Rating

Unknown Analyst

Cantor Fitzgerald

Not Ranked

Cantor Fitzgerald

Buy

―

Reiterated

05/29/25

Mind Medicine (MNMD) Receives a Buy from Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Tsai

Jefferies

$30

Buy

78.15%

Upside

Initiated

01/30/26

Definium Therapeutics initiated with a Buy at JefferiesDefinium Therapeutics initiated with a Buy at Jefferies

Unknown Analyst

Robert W. Baird

Not Ranked

Robert W. Baird

$16→$37

Buy

119.71%

Upside

Reiterated

01/29/26

Definium Therapeutics price target raised to $37 from $16 at BairdDefinium Therapeutics price target raised to $37 from $16 at Baird

Patrick Trucchio

H.C. Wainwright

$55

Buy

226.60%

Upside

Reiterated

01/28/26

Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Definium Therapeutics (DFTX)

Brian Abrahams

RBC Capital

$20→$36

Buy

113.78%

Upside

Reiterated

01/23/26

RBC Capital Sticks to Their Buy Rating for Definium Therapeutics (DFTX)

Justin Walsh

JonesTrading

$61

Buy

262.23%

Upside

Reiterated

01/20/26

Definium Therapeutics: Advancing Late-Stage Psychedelic Pipeline and Diversifying Assets Underpin Buy Rating and $61 Target

Ami Fadia

Needham

$28

Buy

66.27%

Upside

Reiterated

01/12/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Francois Brisebois

LifeSci Capital

$32

Buy

90.02%

Upside

Reiterated

01/12/26

Definium Therapeutics: De-Risked Late-Stage Neuropsychiatric Pipeline Positions 2026 as Catalyst-Rich Year Supporting Buy Rating and $32 Target

Rudy Li

Chardan Capital

$20

Buy

18.76%

Upside

Initiated

12/31/25

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT) and Mind Medicine (NASDAQ: MNMD)

Gavin Clark-Gartner

Evercore ISI

$23→$24

Buy

42.52%

Upside

Reiterated

12/18/25

Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Mind Medicine (NASDAQ: MNMD)

Michael Okunewitch

Maxim Group

$18

Buy

6.89%

Upside

Reiterated

11/10/25

Mind Medicine's Strong Financial Position and Clinical Progress Drive Buy Rating

Jay Olson

Oppenheimer

$25

Buy

48.46%

Upside

Reiterated

11/07/25

Oppenheimer Sticks to Its Buy Rating for Mind Medicine (MNMD)

Sumant Kulkarni

Canaccord Genuity

$16→$25

Buy

48.46%

Upside

Reiterated

11/07/25

Mind Medicine price target raised to $25 from $16 at CanaccordMind Medicine price target raised to $25 from $16 at Canaccord

Jason Wittes

Roth MKM

$36

Buy

113.78%

Upside

Reiterated

08/04/25

Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM)

Marc Goodman

Leerink Partners

$20

Buy

18.76%

Upside

Reiterated

08/01/25

Mind Medicine's Promising Pipeline and Financial Stability Drive Buy Rating

Unknown Analyst

Cantor Fitzgerald

Not Ranked

Cantor Fitzgerald

Buy

―

Reiterated

05/29/25

Mind Medicine (MNMD) Receives a Buy from Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Definium Therapeutics

3 Months

xxx

Success Rate

7/9 ratings generated profit

Average Return

+23.12%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +23.12% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

16/18 ratings generated profit

Average Return

+61.16%

reiterated a buy rating last month

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +61.16% per trade.

2 Years

xxx

Success Rate

13/13 ratings generated profit

Average Return

+148.35%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +148.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DFTX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DFTX has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DFTX average Analyst price target in the past 3 months is 32.58.

Each month's total comprises the sum of three months' worth of ratings.

DFTX Financial Forecast

DFTX Earnings Forecast

Next quarter’s earnings estimate for DFTX is -$0.50 with a range of -$0.74 to -$0.37. The previous quarter’s EPS was -$0.78. DFTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.

No data currently available

DFTX Sales Forecast

Next quarter’s sales forecast for DFTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DFTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.

DFTX Stock Forecast FAQ

What is DFTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Definium Therapeutics’s 12-month average price target is 32.58.

What is DFTX’s upside potential, based on the analysts’ average price target?

Definium Therapeutics has 93.49% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DFTX a Buy, Sell or Hold?

Definium Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Definium Therapeutics’s price target?

The average price target for Definium Therapeutics is 32.58. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $61.00 ,the lowest forecast is $18.00. The average price target represents 93.49% Increase from the current price of $16.84.

What do analysts say about Definium Therapeutics?

Definium Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of DFTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Definium Therapeutics (DFTX) Stock Forecast & Price Target

DFTX Analyst Ratings

DFTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Definium Therapeutics

DFTX Analyst Recommendation Trends

DFTX Financial Forecast

DFTX Earnings Forecast

DFTX Sales Forecast

DFTX Stock Forecast FAQ

Detailed List of Analyst Forecasts